Default company panoramic image
3d27413c 1879 4831 aada cd2c3f4fce10

Nexgenia, Inc.

Nexgenia produces proprietary reagents for molecular and cell separations. These reagents enable efficient, low cost, gentler separations of cells in blood.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Seattle, WA, US
  • Currency USD
  • Founded 2011
  • Employees 4
  • Website nexgeniacorp.com

Company Summary

Nexgenia develops and manufactures reagents based on proprietary technology licensed from the UW and developed internally. Nexgenia will sell these reagents to companies for use in their products or manufacturing. In particular Nexgenia intends to work with a limited number of biotechnology companies, enabling them to separate and isolate cells in the most efficient cost-effective manner possible. Nexgenia's is a business to business model.

Team

  • F4a209c3 69c1 445e b7e3 a75f84be643b
    CEO

    Ron Myers was most recently chief legal officer and VP of strategic transactions at the Institute for Systems Biology in Seattle, WA. Myers was also the chief business officer at VLST Corp. and, prior to that, held executive positions at Corixa Corp., Invitrogen, and Pfizer. Ron has structured partnerships with companies in the bio therapeutic and biotech reagents markets. He currently serves on the Board of Directors of WBBA.

Advisors

Previous Investors

  • Default avatar
    W Fund
    Unconfirmed